The Oncosearch | Oncotarget

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus Research Paper

Sarina A. Piha-Paul, Jennifer J. Wheler, Siqing Fu, Charles Levenback, Karen Lu, Gerald S. Falchook, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Razelle Kurzrock

Published Mar 20, 2014 · Vol. 5, No. 7 · pp. 1846-1855

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway Research Paper

Jennifer J. Wheler, Stacy L. Moulder, Aung Naing, Filip Janku, Sarina A. Piha-Paul, Gerald S. Falchook, Ralph Zinner, Apostolia M. Tsimberidou, Siqing Fu, David S. Hong, Johnique T. Atkins, Roman Yelensky, Philip J. Stephens, Razelle Kurzrock

Published Mar 14, 2014 · Vol. 5, No. 10 · pp. 3029-3038

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses Research Paper

Jennifer J. Wheler, David Hong, Stephen G. Swisher, Gerald S. Falchook, Apostolia Maria Tsimberidou, Thorunn Helgason, Aung Naing, Bettzy Stephen, Filip Janku, Philip J. Stephens, Roman Yelensky, Razelle Kurzrock

Published Jun 10, 2013 · Vol. 4, No. 6 · pp. 890-898

Keywords: advanced thymoma, mTOR inhibitors, targeted therapy, thymic carcinoma

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population Research Paper

Jennifer Wheler, Gerald Falchook, Apostolia M. Tsimberidou, David Hong, Aung Naing, Sarina Piha-Paul, Su S. Chen, John Heymach, Siqing Fu, Su S. Chen, Bettzy Stephen, Jansina Y. Fok, Filip Janku, Razelle Kurzrock

Published Jun 4, 2013 · Vol. 4, No. 5 · pp. 772-784

Keywords: EGFR mutation, EGFR wild-type, non-small cell lung cancer, phase I trials, resistance, squamous cell

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Ishwaria Subbiah, Vivek Subbiah, Apostolia M Tsimberidou, Aung Naing, Ahmed Kaseb, Javle Milind, Siqing Fu, David S Hong, Sarina Piha-Paul, Jenifer Wheler, Kenneth Hess, Filip Janku, Gerald Falchook, Robert A Wolff, Razelle Kurzrock

Published Jan 27, 2013 · Vol. 4, No. 1 · pp. 153-162

Keywords: Gallbladder Cancer, Cholangiocarcinoma, Phase 1 trials

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer Research Paper

Gerald S. Falchook, Aung Naing, David S. Hong, Ralph G. Zinner, Siqing Fu, Sarina A. Piha-Paul, Apostolia M. Tsimberidou, Sonia K. Morgan-Linnell, Yunfang Jiang, Christel C. Bastida, Jennifer J. Wheler, Razelle Kurzrock

Published Jan 14, 2013 · Vol. 4, No. 1 · pp. 118-127

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival Research Paper

J Scott Nystrom, John C. Hornberger, Gauri R. Varadhachary, Richard J. Hornberger, Hialy R. Gutierrez, W. David Henner, Shawn H. Becker, Mahul B. Amin, Michael G. Walker

Published Jun 9, 2012 · Vol. 3, No. 6 · pp. 620-628

Keywords: cancer of unknown primary, diagnosis, genomics, clinical utility, tissue of origin

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus Research Paper

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway Research Paper

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses Research Paper

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population Research Paper

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer Research Paper

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus Research Paper

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway Research Paper

Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses Research Paper

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population Research Paper

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials Research Paper

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer Research Paper

Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and survival Research Paper